Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03333616
Title Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Diego Moores Cancer Center La Jolla California 92093 United States Details
Winship Cancer Institute, Emory University Atlanta Georgia 30322 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02115 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field